ArticleOncoimmunology2015
Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark.
Article in Oncoimmunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Targeting β-catenin using XAV939 nanoparticle promotes immunogenic cell death and suppresses conjunctival melanoma progression.International journal of pharmaceutics · 2023Article
- Article
- Trial Watch: experimental TLR7/TLR8 agonists for oncological indications.Oncoimmunology · 2020Review
- Trial watch: STING agonists in cancer therapy.Oncoimmunology · 2020Review
- Trial watch: IDO inhibitors in cancer therapy.Oncoimmunology · 2020Review
- Trial watch: TLR3 agonists in cancer therapy.Oncoimmunology · 2020Review
- Regulation of Blood and Lymphatic Vessels by Immune Cells in Tumors and Metastasis.Annual review of physiology · 2019Review
- Methods for improving the immunogenicity and efficacy of cancer vaccines.Expert opinion on biological therapy · 2018Review
- Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients.Clinical immunology (Orlando, Fla.) · 2018Review
- The efficacy and safety of immune checkpoint inhibitor combination therapy in lung cancer: a systematic review and meta-analysis.OncoTargets and therapy · 2018Review
- PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy.Journal of hematology & oncology · 2017Review
- Cardiovascular Complications Associated With Novel Cancer Immunotherapies.Current treatment options in cardiovascular medicine · 2017Review
- Biomarkers of immunogenic stress in metastases from melanoma patients: Correlations with the immune infiltrate.Oncoimmunology · 2016Article
- Immune evasion pathways and the design of dendritic cell-based cancer vaccines.Discovery medicine · 2016Review
- The continuing evolution of targeted therapy for inflammatory skin disease.Seminars in immunopathology · 2016Review
- Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery.Circulation · 2015Review
- Immune checkpoint inhibitors: therapeutic advances in melanoma.Annals of translational medicine · 2015Review
- A Perspective of Immunotherapy for Breast Cancer: Lessons Learned and Forward Directions for All Cancers.Breast cancer : basic and clinical research · 2015Review
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Results from recent clinical trials demonstrate that a combinatorial immunotherapeutic regimen based on 2 distinct checkpoint blockers, namely, the CTLA4-targeting agent ipilimumab and the PD-1-specific molecule nivolumab, causes objective responses in a majority of subjects with advanced melanoma. These findings revolutionize the treatment of a neoplasm that was considered incurable until recently. Nonetheless, announcing the defeat of melanoma appears premature. Indeed, a sizeable fraction of patients does not respond to ipilimumab plus nivolumab, and the long-term efficacy of this immunotherapeutic regimen has not yet been investigated. Moreover, many patients experience severe side effects, calling for the development of strategies that uncouple the efficacy of ipilimumab plus nivolumab from their toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.